%0 Journal Article %A Anna Duckworth %A Michael A. Gibbons %A Robin N Beaumont %A Andrew R Wood %A Howard Almond %A Katie Lunnon %A Mark A. Lindsay %A Chris J Scotton %A Jess Tyrrell %T A Mendelian randomisation study of smoking causality in IPF compared with COPD %D 2020 %R 10.1101/2020.12.04.20243790 %J medRxiv %P 2020.12.04.20243790 %X In a normal year, the fatal lung disease Idiopathic Pulmonary Fibrosis (IPF) accounts for ∼1% of UK deaths. Smoking is a recognised risk factor for IPF but the question of causality remains unanswered. Here, we used data from the UK Biobank (UKBB) and the well-established genetic technique of Mendelian randomisation (MR) methods to investigate whether smoking is causal for IPF compared with COPD, where causality is established.We looked at observational associations in unrelated Europeans, with 871 IPF cases, 11,413 COPD cases and 366,942 controls. We performed analyses using one-sample MR to test for inferred smoking causality in ever smokers using genetic variants that have a previously demonstrated association with smoking heaviness.Strong associations between disease status and ever having smoked were found in both IPF (OR = 1.52; 95%CI:1.32-1.74; P=2.4×10−8) and COPD (OR= 5.77; 95%CI:5.48-6.07; P<1×10−15). Using MR, a one allele increase in smoking volume genetic risk score was associated with higher odds of COPD in ever smokers, (OR = 4.32; 95%CI:3.37-5.54; P<1×10−15), but no association was seen in IPF (OR=0.55; 95%CI: 0.17-1.81; P=0.33). No association was found between the genetic risk score and disease prevalence in never smokers with IPF (OR = 1.00; 95%CI:0.98-1.02; P=1.00) or COPD (OR = 1.00; 95%CI:0.99-1.01; P=0.53).Although both IPF and COPD are observationally associated with smoking, our analysis provides evidence inferring that the association is causal in COPD but there is no such evidence in IPF. This suggests that other environmental exposures also need consideration in IPF.Competing Interest StatementM. Gibbons has received support to attend conferences and professional fees from Roche and Boehringer-IngelheimFunding StatementA. Duckworth is funded by the GW4 MRC Doctoral Training Partnership. M. Gibbons has received support to attend conferences and professional fees from Roche and Boehringer-Ingelheim. J. Tyrrell is supported by an Academy of Medical Sciences (AMS) Springboard award, which is supported by the AMS, the Wellcome Trust, GCRF, the Government Department of Business, Energy and Industrial strategy, the British Heart Foundation and Diabetes UK [SBF004\1079].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All UK Biobank participants provided written, informed consent, the study was approved by the National Research Ethics Service Committee North West Haydock, and all study procedures were done in accordance with the World Medical Association Declaration of Helsinki ethical principles for medical research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in analyses are available upon request from UK Biobank at https://www.ukbiobank.ac.uk %U https://www.medrxiv.org/content/medrxiv/early/2020/12/07/2020.12.04.20243790.full.pdf